Triglyceride-Glucose Index and Early Renal Dysfunction in Adults With Type 2 Diabetes
DOI:
https://doi.org/10.61336/jdme.0501.04Keywords:
Triglyceride-glucose index, type 2 diabetes mellitus, renal dysfunction, albuminuriaAbstract
The triglyceride-glucose (TyG) index is a simple surrogate marker of insulin resistance and has been associated with several cardiometabolic complications. Its relationship with early renal dysfunction in adults with type 2 diabetes mellitus (T2DM) remains of clinical interest, particularly before substantial reduction in estimated glomerular filtration rate occurs. This study evaluated the association between the TyG index and early renal abnormalities in adults with T2DM. A cross-sectional study was conducted among 194 adults with established T2DM and preserved or mildly reduced renal function. Fasting triglycerides and glucose were measured to calculate the TyG index, while serum creatinine, estimated glomerular filtration rate, cystatin C, and urinary albumin-to-creatinine ratio were assessed as indicators of renal status. Participants were categorized into tertiles according to TyG index values. Individuals in the highest TyG tertile demonstrated higher urinary albumin-to-creatinine ratio, lower estimated glomerular filtration rate, higher cystatin C, and greater prevalence of moderately increased albuminuria than participants in the lowest tertile. The TyG index showed positive correlations with urinary albumin-to-creatinine ratio and cystatin C and an inverse correlation with estimated glomerular filtration rate. After adjustment for age, sex, diabetes duration, blood pressure, BMI, HbA1c, and antihypertensive medication, the TyG index remained independently associated with urinary albumin-to-creatinine ratio. Participants in the highest TyG tertile had approximately 2.8-fold greater odds of early renal dysfunction compared with those in the lowest tertile. These findings suggest that the TyG index may provide a practical metabolic marker for identifying adults with T2DM who have an increased likelihood of early renal abnormalities.
References
1. Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M, Martínez-Abundis E, Ramos-Zavala MG, Hernández-González SO, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95(7):3347–3351.
2. Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299–304.
3. Du T, Yuan G, Zhang M, Zhou X, Sun X, Yu X. Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk factors for diabetes. Sci Rep. 2014;4:6506.
4. Zhang M, Wang B, Liu Y, Sun X, Luo X, Wang C, et al. Cumulative increased risk of incident type 2 diabetes mellitus with increasing triglyceride-glucose index. Cardiovasc Diabetol. 2017;16:163.
5. Sánchez-García A, Rodríguez-Gutiérrez R, Mancillas-Adame L, González-Nava V, Díaz González-Colmenero A, Solís RC, et al. Diagnostic accuracy of the triglyceride and glucose index for insulin resistance. Medicine (Baltimore). 2020;99(14):e20117.
6. Wang X, Liu J, Cheng Z, Zhong Y, Chen X, Song X. Triglyceride-glucose index and risk of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21:222.
7. Zhao Q, Zhang TY, Cheng YJ, Ma Y, Xu YK, Li WH, et al. Triglyceride-glucose index as a surrogate marker of insulin resistance for predicting cardiovascular outcomes. Cardiovasc Diabetol. 2021;20:148.
8. Lee SH, Han K, Yang HK, Kim HS, Cho JH, Kwon HS, et al. A novel risk prediction model for incident diabetes using the triglyceride-glucose index. Diabetes Res Clin Pract. 2018;143:336–344.
9. Pan Y, Chen C, Gao X, Zheng Y, Wang J, Zhang J, et al. Triglyceride-glucose index and risk of diabetic kidney disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2022;21:161.
10. Lv W, Wang Y, Zhang Z, Zhao X, Chen Y, Wang H, et al. Triglyceride-glucose index and chronic kidney disease: a systematic review and meta-analysis. Front Endocrinol. 2022;13:1039417.
11. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–2045.
12. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care. 2014;37(10):2864–2883.
13. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a consensus report by the ADA and KDIGO. Diabetes Care. 2022;45(12):3075–3090.
14. Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KAM, Zoungas S, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018.
15. American Diabetes Association Professional Practice Committee. Chronic kidney disease and risk management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
